Introduction The management of moderate-to-severe forms of psoriasis is becoming a
frequent concern in geriatric age due to the higher risk to develop treatment adverse events …

To date, adalimumab (ADA) is the only biotechnology drug approved for the management of
hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became …

Introduction Psoriasis management is challenging, especially in pediatric age for different
factors. The introduction of biologic drugs and oral small molecules (OSM) revolutionized the …

Risankizumab is a humanized IgG monoclonal antibody inhibitor of IL23 and has been
recently approved by the EMA and the FDA for the treatment of moderate to severe plaque …

Introduction Biological treatments deeply changed the management of moderate-to-severe
forms of psoriasis. Among the available biological therapies, interleukin (IL)-17 inhibitors …

Teledermatology represented one of the most important and useful tools during the COVID-
19 pandemic era. Indeed, due to the severe restriction, and to reduce the spread of the …

Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being a
potentially life-threatening condition, characterized by recurring episodes or flares of …

Psoriasis management may be challenging, particularly for moderate-to-severe forms of the
disease. Indeed, conventional systemic treatments are often avoided for contraindications or …

Utilization of telemedicine for dermatology has greatly expanded since the start of the
COVID-19 pandemic, with over 500 new teledermatology studies published since 2020. An …

The outbreak of coronavirus disease 2019 (COVID-19) represented a new worldwide
challenge, strongly impacting on the global economy, overall health and lifestyle. Since …